Valuation: Axsome Therapeutics, Inc.

Market Cap 12.2B 10.66B 9.84B 9.07B 17.09B 1,175B 17.47B 118B 46.24B 575B 45.81B 44.8B 1,981B P/E 2026 *
-115x
P/E 2027 * 42.3x
Enterprise Value 12.09B 10.56B 9.75B 8.98B 16.93B 1,164B 17.31B 117B 45.82B 570B 45.39B 44.4B 1,963B EV / Sales 2026 *
12.3x
EV / Sales 2027 * 7.4x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.97%
1 week-1.63%
Current month-6.03%
1 month-8.79%
3 months+21.70%
6 months+24.66%
Current year+25.93%
1 week 224.7
Extreme 224.7001
240.86
1 month 224.7
Extreme 224.7001
260.19
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/11/26 Sell

Director

-286 0.0006%
6/10/26 Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-5.15%-1.63%+104.92%+213.86% 12.2B
+0.16%+1.94%+23.17%-6.12% 69.07B
+0.67%-4.28%+41.06%+201.69% 51.77B
+0.94%+39.60%+39.60%+39.60% 43.63B
+1.12%-1.76%-50.16%-52.75% 40.89B
-1.59%+3.41%+60.03%-26.03% 30.84B
-0.17%-9.37%+92.14%-49.54% 25.06B
-0.99%+0.37%+69.92%+91.78% 23.3B
-5.57%+3.01%+3.19%+174.11% 20.92B
-0.86%-3.55%+63.18%+127.04% 16.71B
Average -1.01%-1.88%+44.70%+71.37% 33.44B
Weighted average by Cap. -0.39%-1.48%+34.67%+54.00%

Financials

2026 *2027 *
Net sales 979M 856M 789M 728M 1.37B 94.27B 1.4B 9.44B 3.71B 46.17B 3.68B 3.6B 159B 1.59B 1.39B 1.29B 1.19B 2.23B 154B 2.28B 15.37B 6.05B 75.22B 5.99B 5.86B 259B
Net income -107M -93.83M -86.58M -79.8M -150M -10.34B -154M -1.03B -407M -5.06B -403M -394M -17.43B 310M 271M 250M 230M 434M 29.86B 444M 2.99B 1.18B 14.62B 1.16B 1.14B 50.34B
Net Debt -111M -96.74M -89.27M -82.28M -155M -10.66B -159M -1.07B -420M -5.22B -416M -407M -17.97B -394M -344M -318M -293M -552M -37.92B -564M -3.8B -1.49B -18.57B -1.48B -1.45B -63.94B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-17 $229.97 -2.98% 627,919
26-07-16 $237.04 -0.21% 639,658
26-07-15 $237.53 +0.96% 838,870
26-07-14 $235.26 +3.06% 482,756
26-07-13 $228.28 -2.36% 843,010
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
237.04USD
Average target price
280.39USD
Spread / Average Target
+18.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock